In November 2020, Segreto and Deigin wrote that the "genetic structure of SARS-CoV-2 does not rule out a laboratory origin" and found that the "SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation." [1]
Qiu. [2]
Magnovvig ( talk · contribs · deleted contribs · logs · filter log · block user · block log)
Definitions from Wiktionary
Media from Commons
News from Wikinews
Quotations from Wikiquote
Texts from Wikisource
Textbooks from Wikibooks
Resources from Wikiversity
EU-China CAI
The EU-China Comprehensive Agreement on Investment (CAI) is a bilateral treaty between the European Union and the People's Republic of China concerning investment between the parties, but not trade. It has been under negotiation since 2014. [3] The negotiations on the text have concluded on 2020-12-30 following personal involvement of Xi Jinping. [4]
History
In May 2021, the von der Leyen Commission suspended efforts to ratify the CAI because "China [had] imposed sanctions on several high-profile members of the European Parliament, three members of national parliaments, two EU committees, and several China-focused European academics" in response to their questions on the Xinjiang genocide and the application of sanctions on four officials from that province. Trade commissioner Valdis Dombrovskis said: "the environment is not conducive to the ratification of the agreement." [5]
References
- ^ Segreto, Rossana; Deigin, Yuri (2020). "The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin". BioEssays. 43 (3): e2000240. doi: 10.1002/bies.202000240. PMC 7744920. PMID 33200842.
-
^ .
doi:
10.1038/scientificamerican0620-24 (inactive 2022-06-26).
{{ cite journal}}: Cite journal requires|journal=( help); Missing or empty|title=( help)CS1 maint: DOI inactive as of June 2022 ( link) - ^ "EU-China Comprehensive Agreement on Investment". European Commission DG Trade. 27 April 2020. Retrieved 4 June 2020.
- ^ "EU and China reach agreement in principle on investment". European Comission.
- ^ Devonshire-Ellis, Chris (5 May 2021). "The EU Suspends Ratification of CAI Investment Agreement with China: Business and Trade Implications". Dezan Shira & Associates. China Briefing.
GeneOne
GeneOne Life Science (GLS) is a KOSPI-listed company headquartered in Seoul, South Korea. The company, whose entry into biotechnology began in 2005, "is focused on gene-based therapies and vaccines". The company changed names twice, from Dong-Il Fabric to VGXI International to its current label in 2014. Its "global clinical development group is based in Blue Bell, Pennsylvania. VGXI Inc. is a wholly owned subsidiary and is based in Woodlands, Texas. VGXI is known as the largest Contract Manufacturing Organization able to supply cGMP-grade DNA plasmids for clinical use. [1]
History
Before August 2016, GLS began tests of a DNA vaccine against Zika in Miami, due to the outbreak there which had infected at least 14 people. The injection technique of electroporation is employed by GLS, in which " genes from the virus are shot under high pressure into a person’s arm." [1] [2]
In April 2020, GLS and Inovio shared positive results for their MERS DNA vaccine. [3]
In May 2020, GLS announced FDA approval of a Phase 2 Study of their GLS-1200 nasal spray product for COVID-19 prevention. Their product seeks to train cells to produce nitric oxide which "has been shown to inhibit SARS coronavirus growth and infectivity... The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use." [4]
References
- ^ a b Maslow, Joel (2018). "Gene One life science". Human Vaccines & Immunotherapeutics. 14 (11): 1–2. doi: 10.1080/21645515.2018.1507374. PMC 6314400. PMID 30346869.
- ^ Regalado, Antonio (2 August 2016). "The U.S. government has begun testing its first Zika vaccine in humans". MIT Technology Review Magazine. Retrieved 2016-08-06.
- ^ "INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference". INOVIO Pharmaceuticals. 28 April 2020.
- ^ "GeneOne Life Science Announces US FDA Approval of a Phase 2 Study of GLS-1200 Nasal Spray for COVID-19 Prevention". Vocus PRW Holdings, LLC. PRWeb. 4 May 2020.
Category:Biotechnology Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Research and development in the United States Category:Life sciences industry Category:Pharmaceutical companies of South Korea Category:Biotechnology companies of South Korea Category:Companies listed on KOSPI Category:Applied genetics Category:Bioethics Category:Biotechnology Category:Medical genetics Category:Molecular biology Category:Gene delivery Category:Genetic engineering Category:Zika virus Vaccine Category:Medical research Category:Medical responses to the COVID-19 pandemic Category:Vaccines
Timothy Grayson has been an official at DARPA since at least 2004, when it began the DARPA Grand Challenge for driverless off-road vehicles. [1] Grayson has worked on the DARPA AlphaDogfight.
Grayson spent "several years as a senior intelligence officer with the Central Intelligence Agency (CIA) in the Directorate of Science and Technology", and has worked for the Office of the Director of National Intelligence. [2]
Grayson was invited to speak at the 2019 MILCOM conference, [2] and shared a stage with the IEEE President-elect in a panel discussion at the 2020 IEEE Rising Stars Global conference. [3]
References
- ^ "DARPA Challenges Drive Dual-Use Innovation". SPIE. 30 April 2019.
- ^ a b "Timothy "Tim" Grayson, Ph.D. - Profile". AFCEA International. November 2019.
- ^ "Program". IEEE Rising Stars Global 2020.
Category:Living people Category:DARPA Category:American civil servants
In November 2020, Segreto and Deigin wrote that the "genetic structure of SARS-CoV-2 does not rule out a laboratory origin" and found that the "SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation." [1]
Qiu. [2]
Magnovvig ( talk · contribs · deleted contribs · logs · filter log · block user · block log)
-
Definitions from Wiktionary
-
Media from Commons
-
News from Wikinews
-
Quotations from Wikiquote
-
Texts from Wikisource
-
Textbooks from Wikibooks
-
Resources from Wikiversity
EU-China CAI
The EU-China Comprehensive Agreement on Investment (CAI) is a bilateral treaty between the European Union and the People's Republic of China concerning investment between the parties, but not trade. It has been under negotiation since 2014. [3] The negotiations on the text have concluded on 2020-12-30 following personal involvement of Xi Jinping. [4]
History
In May 2021, the von der Leyen Commission suspended efforts to ratify the CAI because "China [had] imposed sanctions on several high-profile members of the European Parliament, three members of national parliaments, two EU committees, and several China-focused European academics" in response to their questions on the Xinjiang genocide and the application of sanctions on four officials from that province. Trade commissioner Valdis Dombrovskis said: "the environment is not conducive to the ratification of the agreement." [5]
References
- ^ Segreto, Rossana; Deigin, Yuri (2020). "The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin". BioEssays. 43 (3): e2000240. doi: 10.1002/bies.202000240. PMC 7744920. PMID 33200842.
-
^ .
doi:
10.1038/scientificamerican0620-24 (inactive 2022-06-26).
{{ cite journal}}: Cite journal requires|journal=( help); Missing or empty|title=( help)CS1 maint: DOI inactive as of June 2022 ( link) - ^ "EU-China Comprehensive Agreement on Investment". European Commission DG Trade. 27 April 2020. Retrieved 4 June 2020.
- ^ "EU and China reach agreement in principle on investment". European Comission.
- ^ Devonshire-Ellis, Chris (5 May 2021). "The EU Suspends Ratification of CAI Investment Agreement with China: Business and Trade Implications". Dezan Shira & Associates. China Briefing.
GeneOne
GeneOne Life Science (GLS) is a KOSPI-listed company headquartered in Seoul, South Korea. The company, whose entry into biotechnology began in 2005, "is focused on gene-based therapies and vaccines". The company changed names twice, from Dong-Il Fabric to VGXI International to its current label in 2014. Its "global clinical development group is based in Blue Bell, Pennsylvania. VGXI Inc. is a wholly owned subsidiary and is based in Woodlands, Texas. VGXI is known as the largest Contract Manufacturing Organization able to supply cGMP-grade DNA plasmids for clinical use. [1]
History
Before August 2016, GLS began tests of a DNA vaccine against Zika in Miami, due to the outbreak there which had infected at least 14 people. The injection technique of electroporation is employed by GLS, in which " genes from the virus are shot under high pressure into a person’s arm." [1] [2]
In April 2020, GLS and Inovio shared positive results for their MERS DNA vaccine. [3]
In May 2020, GLS announced FDA approval of a Phase 2 Study of their GLS-1200 nasal spray product for COVID-19 prevention. Their product seeks to train cells to produce nitric oxide which "has been shown to inhibit SARS coronavirus growth and infectivity... The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use." [4]
References
- ^ a b Maslow, Joel (2018). "Gene One life science". Human Vaccines & Immunotherapeutics. 14 (11): 1–2. doi: 10.1080/21645515.2018.1507374. PMC 6314400. PMID 30346869.
- ^ Regalado, Antonio (2 August 2016). "The U.S. government has begun testing its first Zika vaccine in humans". MIT Technology Review Magazine. Retrieved 2016-08-06.
- ^ "INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference". INOVIO Pharmaceuticals. 28 April 2020.
- ^ "GeneOne Life Science Announces US FDA Approval of a Phase 2 Study of GLS-1200 Nasal Spray for COVID-19 Prevention". Vocus PRW Holdings, LLC. PRWeb. 4 May 2020.
Category:Biotechnology Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Research and development in the United States Category:Life sciences industry Category:Pharmaceutical companies of South Korea Category:Biotechnology companies of South Korea Category:Companies listed on KOSPI Category:Applied genetics Category:Bioethics Category:Biotechnology Category:Medical genetics Category:Molecular biology Category:Gene delivery Category:Genetic engineering Category:Zika virus Vaccine Category:Medical research Category:Medical responses to the COVID-19 pandemic Category:Vaccines
Timothy Grayson has been an official at DARPA since at least 2004, when it began the DARPA Grand Challenge for driverless off-road vehicles. [1] Grayson has worked on the DARPA AlphaDogfight.
Grayson spent "several years as a senior intelligence officer with the Central Intelligence Agency (CIA) in the Directorate of Science and Technology", and has worked for the Office of the Director of National Intelligence. [2]
Grayson was invited to speak at the 2019 MILCOM conference, [2] and shared a stage with the IEEE President-elect in a panel discussion at the 2020 IEEE Rising Stars Global conference. [3]
References
- ^ "DARPA Challenges Drive Dual-Use Innovation". SPIE. 30 April 2019.
- ^ a b "Timothy "Tim" Grayson, Ph.D. - Profile". AFCEA International. November 2019.
- ^ "Program". IEEE Rising Stars Global 2020.
Category:Living people Category:DARPA Category:American civil servants